199 related articles for article (PubMed ID: 33565048)
21. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
[TBL] [Abstract][Full Text] [Related]
22. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
[TBL] [Abstract][Full Text] [Related]
23. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values.
Shah KK; Ramos-Goñi JM; Kreimeier S; Devlin NJ
Eur J Health Econ; 2020 Sep; 21(7):1091-1103. PubMed ID: 32506281
[TBL] [Abstract][Full Text] [Related]
24. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
25. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
26. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
27. 'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L.
Åström M; Conte H; Berg J; Burström K
Qual Life Res; 2022 Jul; 31(7):2133-2142. PubMed ID: 35201557
[TBL] [Abstract][Full Text] [Related]
28. Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off.
Paveliu MS; Olariu E; Caplescu R; Oluboyede Y; Niculescu-Aron IG; Ernu S; Vale L
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299864
[TBL] [Abstract][Full Text] [Related]
29. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents.
Åström M; Rolfson O; Burström K
Appl Health Econ Health Policy; 2022 May; 20(3):383-393. PubMed ID: 35083734
[TBL] [Abstract][Full Text] [Related]
30. EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set.
Kreimeier S; Greiner W
Value Health; 2019 Jan; 22(1):31-37. PubMed ID: 30661631
[TBL] [Abstract][Full Text] [Related]
31. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
32. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states.
Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE
Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793
[TBL] [Abstract][Full Text] [Related]
33. EQ-5D-5L: a value set for Romania.
Olariu E; Mohammed W; Oluboyede Y; Caplescu R; Niculescu-Aron IG; Paveliu MS; Vale L
Eur J Health Econ; 2023 Apr; 24(3):399-412. PubMed ID: 35688994
[TBL] [Abstract][Full Text] [Related]
34. Valuing EQ-5D-Y: the current state of play.
Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
[TBL] [Abstract][Full Text] [Related]
35. An experience- and preference-based EQ-5D-3L value set derived using 18 months of longitudinal data in patients who sustained a fracture: results from the ICUROS.
Svedbom A; Borgstöm F; Hernlund E; Alekna V; Bianchi ML; Clark P; Diaz-Curiel M; Dimai HP; Jürisson M; Lesnyak O; McCloskey E; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jönsson B; Kanis JA
Qual Life Res; 2023 Apr; 32(4):1199-1208. PubMed ID: 36495384
[TBL] [Abstract][Full Text] [Related]
36. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
[TBL] [Abstract][Full Text] [Related]
37. The EQ-5D-3L Valuation Study in Pakistan.
Malik M; Gu NY; Hussain A; Roudijk B; Purba FD
Pharmacoecon Open; 2023 Nov; 7(6):963-974. PubMed ID: 37702988
[TBL] [Abstract][Full Text] [Related]
38. Valuing health-related quality of life: An EQ-5D-5L value set for England.
Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
[TBL] [Abstract][Full Text] [Related]
39. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]